期刊文献+

贝利尤单抗治疗儿童系统性红斑狼疮的研究进展 被引量:5

Progress in the Treatment of Systemic Lupus Erythematosus in Children with Belizumab
下载PDF
导出
摘要 儿童系统性红斑狼疮(cSLE)属于自身免疫性疾病的一种,其发病机制尚未完全清楚,但B细胞的异常激活是系在其发病过程中起到了关键作用,贝利尤单抗是一种人源化单克隆抗体,可选择性识别、阻止血清中游离B淋巴细胞刺激因子,是一种有发展前景的治疗SLE的生物制剂。
作者 史卓 高春林 夏正坤 孙涛 张沛 Shi Zhuo;Gao Chunlin;Xia Zhengkun
机构地区 东部战区总医院
出处 《中国中西医结合皮肤性病学杂志》 CAS 2021年第4期413-415,共3页 Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
基金 江苏省科技项目BE2017719 江苏省科技项目BK20190251 江苏省卫生计生委CXTDA2017022 江苏省博士后科研资助计划2018K089B 中国博士后科学基金项目2018M643888。
  • 相关文献

参考文献3

二级参考文献21

  • 1Mackay F, Schneider P. Cracking the BAFF code [ J ]. Nat Rev Im- munol,2009,9 (7) :491-502.
  • 2Davidson A. Targeting BAFF in autoimmunity[ J]. Curr Opin Immu- nol,2010,22(6) :732-739.
  • 3Ramanujam M. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice[J]. Arthritis Rheum,2010,62(5) :1457-1468.
  • 4Jacob CO. Paucity of clinical disease despite serological autoirranunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice de- ficient in BAFF[J]. J Immunol,2006,177(4) :2671-2680.
  • 5Liu Z, A Davidson. BAFF inhibition: a new class of drugs for the treatment of autoimmunity [ J ]. Exp Cell Res, 2011,317 ( 9 ) : 1270- 1277.
  • 6Halpern WG. Chronic administration of belimumab, a BLyS antago- nist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys : pharmacokinetic, pharmacodynamic and toxicologic effects[ J]. Toxicol Sci,2006,91 (2) :586-599.
  • 7Auyeung-Kim DJ. Developmental and peri-postnatal study in cyno- molgus monkeys with belimumab, a monoclonal antibody directed a- gainst B-lymphocyte stimulator [ J ]. Reprod Toxicol, 2009,28 ( 4 ) : 4.4-3 -455.
  • 8Wallace DJ. A phase II , randomized, double-blind, placebo-con- trolled, dose-ranging study of belimumab in patients with active sys- temic lupus erythematosus [ J ]. Arthritis Rheum, 2009,61 ( 9 ) : 1168-1178.
  • 9Navarra SV. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus : a randomised, placebo-controlled, phase 3 trial[ J]. Lancet,2011,377 (9767) :721-731.
  • 10Furie R. A phase II, randomized, placebo-controlled study of heli- mumab, a monoclonal antibody that inhibits B lymphocyte stimula- tor, in patients with systemic lupus erythematosus [ J]. Arthritis Rheum ,2011,63 (12) :3918-3930.

共引文献10

同被引文献42

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部